Form 4: Eli Lilly CEO Ricks Disposes of Shares

Eli Lilly & Co. CEO David A. Ricks reported a disposition of 24,750 common shares on November 10, 2025, through a non-sale transaction.

Summary

• David A. Ricks, President, Chair, and CEO of Eli Lilly & Co., filed a Form 4 reporting changes in beneficial ownership.
• The filing details a disposition of 24,750 shares of Eli Lilly & Co. common stock on November 10, 2025.
• This transaction was coded 'G', indicating a gift or grant, with a reported price of $0 per share.
• Following this transaction, David A. Ricks directly owns 515,166.167 shares of common stock.
• Indirect beneficial ownership includes 6,685 shares in a 2025 Grantor Retained Annuity Trust (GRAT), 54,117 shares in a 2022 GRAT, 300 shares by Trust, 68,656 shares in a David A. Ricks SLAT, and 7,305.09 shares in a 401(k).
• An earlier transfer of 6,685 shares of common stock to a 2025 Grantor Retained Annuity Trust, where Ricks is the trustee, occurred on September 9, 2025.

Sentiment

Score: 5

Explanation: The filing reports a disposition of shares by the CEO, which is a routine insider transaction often related to personal financial or estate planning, rather than a direct reflection of company performance or outlook. The transaction was a non-sale disposition (Code G, $0 price).

Future Outlook

NA

Industry Context

NA

Related Party Transactions

• Transfer of 6,685 shares of Eli Lilly and Company common stock to a 2025 Grantor Retained Annuity Trust (GRAT) on September 9, 2025, where David A. Ricks is the trustee.
• Indirect beneficial ownership of 54,117 shares through a 2022 Grantor Retained Annuity Trust (GRAT).
• Indirect beneficial ownership of 300 shares by Trust.
• Indirect beneficial ownership of 68,656 shares by David A. Ricks SLAT.

Key Dates

Keywords

Eli Lilly, LLY, David A. Ricks, Form 4, insider transaction, common stock, share disposition, CEO, director